CYTEK(US:CTKB) Globenewswire·2026-01-12 10:00Core Insights - Cytek Biosciences, Inc. announced preliminary, unaudited revenue results for Q4 and full year 2025, expecting total revenue of approximately $201 million for the year and about $62 million for Q4, reflecting growth of 8% year-over-year and 19% quarter-over-quarter [2][3] Financial Performance - The expected revenue for the full year 2025 is approximately $201 million [2] - Q4 2025 revenue of approximately $62 million shows an 8% increase compared to Q4 2024 and a 19% increase compared to Q3 2025 [2] Growth Drivers - The growth in Q4 2025 is attributed to strong performance in Services, Reagents, and instrument revenue in the Asia Pacific region, along with improved instrument sales in the US and EMEA [3] - The CEO highlighted a return to positive growth in instrument sales in EMEA during Q4 [3] Future Outlook - The company believes it is well-positioned for sustainable growth and profitability in the flow cytometry market [3] - Cytek plans to report comprehensive financial results for Q4 and full year 2025 and provide guidance for 2026 during an earnings call expected in late February 2026 [3] Company Overview - Cytek Biosciences specializes in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ technology to enhance cell analysis tools [5] - The company's product offerings include various flow cytometers, reagents, and software, aimed at providing integrated solutions for customers [5]